Drug Profile
PRC 062
Latest Information Update: 25 Feb 2016
Price :
$50
*
At a glance
- Originator Purdue Pharma
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 24 Feb 2016 No recent reports on development identified - Phase-III for Pain in Canada (unspecified route)
- 31 Jul 2014 Purdue Pharma completes a phase III trial in non-cancer Pain in Canada (ISRCTN54273961)
- 01 Nov 2013 Phase-III clinical trials in Pain (non-cancer pain) in Canada (unspecified route)